A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control administration groups.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taejoon Pharmaceutical Co., Ltd.
• Treatments: Latanoprost

Criteria

• Inclusion Criteria:

• Male or female, age 19 or over

• Written informed consent to participate in the trial

• Exclusion Criteria:

• Any other Galucoma except POAG(ex, Closed anterior chamber angle, angle-closure glaucoma)

• Any laser or ocular surgery within 3months prior screening

• Use of contact lenses

• Known reactive airways disease

• Any condition limiting patient's ability to participate in the trial